As part of its efforts to unify all diabetes relevant device data into a single platform, Glooko is partnering with continuous glucose monitoring (CGM) system maker Dexcom and Insulet Corporation, the leader in tubeless insulin pump technology with its OmniPod Insulin Management System.
Under the deal, Glooko will deliver its next generation product that includes both Dexcom CGM and Insulet’s OmniPod pump data this summer, adding data from both systems into its platform, which already sing along more than 30 blood glucose (BG) monitors (over 90% market share) and the most popular fitness and biometric tools. Patients can also record food intake and medication and insulin dosage to provide context around changes in their blood glucose readings.
“We are pleased to be partnering with Glooko to add Dexcom CGM data to their comprehensive diabetes management platform,” Kevin Sayer, CEO of Dexcom, said in a statement. “We believe that Glooko’s platform which accesses Dexcom data through our “open architecture” can be a very meaningful tool for our patients to manage their diabetes.”
Dexcom’s CGM data and Insulet’s OmniPod’s pump data will be brought into Glooko and structured for patients and their healthcare providers in a simple to interpret view in both the Glooko mobile app and via Glooko’s Population Tracker. Glooko will access data from these devices directly, in addition to pulling data from the Apple HealthKit.
Using Glooko, healthcare providers can engage at-risk patients before costly intervention and hospitalizations occur. In addition, the platform enables both providers and patients to understand and analyze diabetes data, and set reminders for improved treatment plan adherence.
“Now OmniPod patients will have the ability to view their insulin delivery, blood glucose and CGM data together,” Patrick Sullivan, President and CEO of Insulet Corporation, said in a statement. “This collaboration furthers our shared vision of helping to make life with diabetes easier by providing greater access to the data people living with diabetes need to make smart and effective decisions to realize better control.”
The announcement comes on the heels of Glooko’s recent Series B investment that brought $16.5M of additional funds into the business. That money will be used to fuel expansion of Glooko’s FDA-cleared, HIPAA-compliant platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms.